Reporting and Publication of Postmarket Clinical Trials for Novel Drugs Approved by the FDA
JAMA Network Open · 23.07.2026 · 9 (7) · e2624832
DOI: 10.1001/jamanetworkopen.2026.24832 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 23.07.2026. Verfasst von Maximilian Siebert und 2 weiteren Autor:innen. Beteiligte Einrichtung: Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, Massachusetts. Die Arbeit nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
This cross-sectional study describes methods and timing of dissemination of the results of efficacy and safety trials outlined in postmarketing requirements for novel drugs approved by the US Food and Drug Administration (FDA).
Autor:innen und Institutionen
- Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, Massachusetts.
- Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia.
- Computational Health Informatics Program, Boston Children's Hospital, Boston, Massachusetts.
- Department of Pediatrics, Harvard Medical School, Boston, Massachusetts.
Zitieren
APA
Siebert, M., Wallach, J. D., & Bourgeois, F. T. (2026). Reporting and Publication of Postmarket Clinical Trials for Novel Drugs Approved by the FDA. JAMA Network Open, 9(7), e2624832. https://doi.org/10.1001/jamanetworkopen.2026.24832
Vancouver
Siebert M, Wallach JD, Bourgeois FT. Reporting and Publication of Postmarket Clinical Trials for Novel Drugs Approved by the FDA. JAMA Network Open. 2026;9(7):e2624832. doi:10.1001/jamanetworkopen.2026.24832
BibTeX
@article{Siebert2026,
author = {Siebert, Maximilian and Wallach, Joshua D and Bourgeois, Florence T},
title = {Reporting and Publication of Postmarket Clinical Trials for Novel Drugs Approved by the FDA},
journal = {JAMA Network Open},
year = {2026},
volume = {9},
number = {7},
pages = {e2624832},
doi = {10.1001/jamanetworkopen.2026.24832}
}
EUVIMED